|Home | About | Journals | Submit | Contact Us | Français|
In the world of infectious diseases, the confidence of the 1960s and 1970s has given way to a stark realization that our mastery of the microbial world is not absolute — as the emergence of SARS and of avian influenza has illustrated. The current outbreak of Clostridium difficile associated diarrhea (CDAD) in Montréal and other areas of Quebec is a harsh reminder that even well-known bacteria can change their behaviour and become emerging threats.
In this issue, Susan Poutanen and Andrew Simor provide a detailed review of the epidemiology, pathogenesis, clinical presentation, diagnosis, treatment and control of CDAD.1 Despite this knowledge, the incidence of CDAD continues to increase in many hospitals across Canada, the United States and elsewhere. The US Centers for Disease Control and Prevention have analyzed secular trends in the incidence of CDAD and reported a steady increase from 1987 to 2001.2 Of 440 infectious disease physicians in the US who participated in a recent Web-based poll, 30% reported that they are seeing higher rates of CDAD, more severe fulminant CDAD and more relapsing CDAD than in the past.
During the past 18 to 24 months, many health care institutions in Montréal and other regions of Quebec have experienced a rise in the CDAD incidence (mean 28.2 per 1000 admissions, range 12.8–45.0 per 1000 admissions), which is about 4 to 5 times the rate of 2 years ago and 5 times the national average in 1997.3 There is an overall impression that there has been an increase in the proportion of CDAD cases with severe and fatal complications and an increase in the relapse rate among affected patients. A 1997 Canadian survey4 indicated that the attributable case-fatality rate to be 1.5%, and other authors have reported an attributable mortality of 0.8 to 2% for nosocomial CDAD.5,6 Five months ago, an ad hoc group formed by several Quebec medical microbiologists was established in light of concern about the rising CDAD incidence and its complication rates: this is now called the CDAD Clinical Study Investigators (CDAD- CSI) group. The group has established 4 priorities: (1) to establish the true incidence and serious complication rate of CDAD in affected participating Quebec hospitals by using standardized definitions and methods; (2) to begin in vitro studies of the bacteria in affected hospitals to determine whether increased virulence factors are present; (3) to establish urgent research protocols for therapy; and (4) to devise newer ultra-rapid methods of diagnosis.
The CDAD-CSI group has generated several hypotheses that may explain the current multicentre outbreak, as follows:
Many infection control measures have been implemented, including contact precautions, dedicated equipment for infected patients when possible, disposable thermometers, early empirical treatment of suspected cases, infection prevention and control education for personnel, an emphasis on hand hygiene, intensified housekeeping in high-incidence units, sporicidal agents for environmental disinfection, review and potential restriction of antibiotics, and decreased turnaround time for C. difficile test results.
Despite these measures, no hospital in our group has been able to bring the CDAD rate to its pre-epidemic rate. Why have we not been able to break the cycle of transmission? Several obstacles hamper control measures. In an outbreak situation, spore burdens are high and require increasing intensity of environmental disinfection. In most hospitals, the housekeeping staff was already working at full capacity before the outbreak. Overburdened health care workers have had difficulty coping with the increased numbers of patients in isolation. Inadequate numbers of single rooms with dedicated bathroom facilities also facilitate transmission. Let us remember that other infectious patients also require vigilant isolation, such as those with MRSA, VRE, measles, chicken pox and tuberculosis, to name a few. The paucity of adequate handwashing facilities further compounds the problem. Improved methods to monitor antibiotic utilization are required. Taken together, this highlights the lack of surge capacity to fully combat the outbreak.
A number of unanswered questions remain. If this current strain is different, where has it come from? Why do some infected patients have serious complications, while other seemingly similar patients experience a relatively benign course? How can we prevent the occurrence of severe complications? The answers to these questions would improve our understanding of this disease and its control. It is only through a concerted and coordinated approach, coupled with increased resources and funding, that expeditious answers will be found to the current dilemma and patient safety will be assured.
β See related articles pages 19, 27, 33, 45 and 51
Contributors: Vivian Loo initiated and coordinated the commentary and, with Michael Libman and Mark Miller, drafted the commentary. All authors provided data included in the commentary, revised the draft critically for important intellectual content and approved the final version.
Competing interests: None declared.
Correspondence to: Dr. Vivian G. Loo, Infection Control Service, Hôpital général de Montréal, D16.168–1650 ave. Cedar, Montréal QC H3G 1A4; fax 514 934-8427; email@example.com